How precision oncology is improving care for patients with early-stage cancer

For patients with early-stage cancer, precision oncology can be used to tailor treatment based on a patient’s risk of recurrence by also looking at circulating tumor DNA (ctDNA) levels. Knowing how much ctDNA is in a patient’s blood after surgery helps doctors consider whether to deploy additional treatment options or tighter surveillance. This allows doctors to be more precise in personalizing the management of their patients with early-stage cancer.

Our Guardant Reveal™ test is the first blood-only test for residual disease and recurrence monitoring.